Clinical Trial Update: PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pirfenidone versus placebo to prevent acute radiation-induced lung injury in breast cancer patients receiving hypofractionated radiot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Radiation-induced Lung Injury

Drugs mentioned

• Esbriet (pirfenidone) (pirfenidone)

Snippet

Sponsor: Fujian Medical University Union Hospital | Conditions: Acute Lung Injury, Prevention | Phase 2 | Status: RECRUITING